Phytochem Remedies (India) Ltd IPO Opens Today: Price Band Set ₹98.00 Per Share

Mumbai, 18 December 2025: Corrugated boxes and boards manufacturer Phytochem Remedies (India) Ltd announced that its Rs 38.2 crore initial share sale is open for public subscription today, December 18, 2025. The initial public offering (IPO) will conclude on December 22. The IPO is entirely a fresh issue of 39 lakh equity shares at a price of ₹98 per scrip worth ₹38.22 crore.

Incorporated in 2002, Phytochem Remedies is a manufacturer of corrugated boxes and corrugated board solutions, catering primarily to industries such as food & beverages, FMCG, pesticides, pharmaceuticals, and automotive. The company operates from its strategically located manufacturing units in Bari Brahmana, Jammu. Its products include corrugated boxes (3-ply, 5-ply, and 7-ply), printed corrugated boxes, corrugated rolls, and corrugated pads and sheets.

Phytochem Remedies ₹38.22 Crore Entirely Fresh Issue; Lot Size at 1200; Price Band at Fixed Price of ₹98.00 

Phytochem Remedies IPO is a fixed price issue of ₹38.22 crores. The issue is entirely a fresh issue of 0.39 crore shares of ₹38.22 crore. The IPO opens for subscription on December 18, 2025, and closes on December 22, 2025. The allotment for the Phytochem Remedies IPO is expected to be finalised on December 23, 2025. Phytochem Remedies IPO will list on BSE SME with a tentative listing date fixed as December 26, 2025.

Phytochem Remedies IPO price is ₹98.00 per share. The lot size for an application is 1,200. The minimum amount of investment required by an individual investor (retail) is ₹2,35,200.00 (2,400 shares) (based on upper price). The minimum lot size investment for HNI is 3 lots (3,600 shares), amounting to ₹3,52,800.

Mefcom Capital Markets Ltd. is the book running lead manager and Bigshare Services Pvt.Ltd. is the registrar of the issue. The Market Maker of the company is Aftertrade Broking Pvt.Ltd..

Phytochem Remedies Proceeds to be Used towards Capital Expenditure and Debt Repayment

The net proceeds from the fresh issue will be used to fund capital expenditure requirements for the purchase of equipment/machineries and towards civil construction (₹19.48crore), repayment/pre-payment, in full or in part, of certain borrowings availed by the company (₹9.37 crore), and for general corporate purposes (₹5.64 crore)

Phytochem Remedies Financial Performance Up 12% in Revenues and PAT Surges 94%

Phytochem Remedies showed robust financial growth from FY24 to FY25 with a 12% growth in revenues and a staggering 94% growth in profit after taxes. Its gross income rose from ₹32.90 crore in FY24 to ₹36.81 crore in FY25, and its assets rose from ₹41.85 crore in FY24 to ₹44.50 crore in FY25, while that of September 2025 touched ₹53.68 crore. EBITDA witnessed strong uptick to ₹8.69 crore in FY25 compared to FY24 which stood at ₹5.88 crore. Profit after tax nearly doubled from ₹2.31 crore in FY24 to ₹4.48 crore in FY255. 

Phytochem Remedies Key Metrics Highlight 34.07% ROE and Strong Profit Margins

Phytochem Remedies (India) Ltd. showed operational efficiency as indicated by its KPIs. The company recorded healthy return on equity and return on net worth at 34.07%, supported by robust ROCE of 25.29%. At the profitability level, the company’s posted good PAT, with a profit margin of 12.25% and EBITDA margin of 23.78%. The debt-equity ratio was 1.42, indicating a manageable leverage, and the price to book value was at 2.35 showing positive market confidence in the fundamentals of the company.

Source:https://www.bseindia.com/markets/publicIssues/DisplayIPO.aspx?id=4366&type=FPO&idtype=1&status=L&IPONo=7508&startdt=18/Dec/2025

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur. 

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com. 

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations